Skip to content
The Great News – Lifestyle
Home
Sample Page
Author:
Oncolytics Biotech, Inc.
Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep’s Potential Across Gastrointestinal Tumors
May 26, 2026
Oncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer
May 5, 2026
Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study
April 29, 2026
Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer
April 6, 2026
Oncolytics Biotech® Completes Domicile Change to the United States
April 1, 2026
Oncolytics Biotech® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026
March 19, 2026